Journal Information
Vol. 34. Issue 11.
Pages 705-706 (November 2015)
Vol. 34. Issue 11.
Pages 705-706 (November 2015)
Letter to the Editor
Open Access
Comment on “Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting”
Comentário a estudo de custo-efetividade de rivaroxabano para prevenção de acidente vascular cerebral em doentes com fibrilhação auricular em Portugal
Visits
4432
Luís Silva Miguel
Centro de Investigação Sobre Economia Portuguesa, Instituto Superior de Economia e Gestão, Lisboa, Portugal
This item has received

Under a Creative Commons license
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

As a health economist, with a particular interest in the economic evaluation of drugs, I was pleased to read the article “Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting” by Morais et al. in volume 33, issue 9, of the Journal.1

It is increasingly clear that as well as the criteria of efficacy, safety and quality that are required for market authorization, the cost-effectiveness of a drug should also be taken into consideration. This is essential to ensure the best use of resources and thus better health outcomes.

Of course, this objective can only be fully achieved if the medical community has access to studies published in journals of recognized scientific quality and prestige.

However, despite improvements over the last 15 years, a significant proportion of the medical community lacks the necessary tools to perform a critical analysis of a study's results or to identify factors that could affect them. It is thus essential that at least the main parameters used in a particular study should be explained in a transparent fashion.

As the lead author of the article “Economic evaluation of dabigatran for stroke prevention in patients with non-valvular atrial fibrillation”, published in volume 32, issue 7–8, of the Journal,2 I carried out a careful analysis of the results presented by Morais et al. Comparison between the two studies showed that the differences stem from the different financial costs assigned to monitoring patients under warfarin. As readers will naturally compare the two articles, I consider it essential that the authors of the cost-effectiveness study of rivaroxaban clearly specify this parameter.

I would also like to point out that there appears to be an error in Table 4 (“Cost-effectiveness results of base-case analysis”) of the article by Morais et al. In this table, the authors report the total costs for both drugs and separate costs for drug acquisition, drug administration, and event treatment. However, the sum of the latter does not equal the total.

Ethical disclosuresProtection of human and animal subjects

The authors declare that no experiments were performed on humans or animals for this investigation.

Confidentiality of data

The authors declare that no patient data appears in this article.

Right to privacy and informed consent

The authors declare that no patient data appears in this article.

Conflicts of interest

The author has no conflicts of interest to declare.

References
[1]
J. Morais, C. Aguiar, E. McLeod, et al.
Estudo de custo-efectividade de rivaroxabano para prevenção de acidente vascular cerebral em doentes com fibrilhação auricular em Portugal.
Rev Port Cardiol, 33 (2014), pp. 535-544
[2]
L.S. Miguel, E. Rocha, J. Ferreira.
Avaliação económica do dabigatrano na prevenção de acidentes vasculares cerebrais isquémicos em doentes com fibrilhação auricular não valvular.
Rev Port Cardiol, 32 (2013), pp. 557-565

Please cite this article as: Miguel LS. Comentário a estudo de custo-efetividade de rivaroxabano para prevenção de acidente vascular cerebral em doentes com fibrilhação auricular em Portugal. Rev Port Cardiol. 2015;34:705–706.

Copyright © 2015. Sociedade Portuguesa de Cardiologia
Download PDF
Idiomas
Revista Portuguesa de Cardiologia (English edition)
Article options
Tools
en pt

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

By checking that you are a health professional, you are stating that you are aware and accept that the Portuguese Journal of Cardiology (RPC) is the Data Controller that processes the personal information of users of its website, with its registered office at Campo Grande, n.º 28, 13.º, 1700-093 Lisbon, telephone 217 970 685 and 217 817 630, fax 217 931 095, and email revista@spc.pt. I declare for all purposes that the information provided herein is accurate and correct.